Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for intravenous immune globulin (IVIG) in the treatment of autoimmune mucocutaneous blistering diseases, effective May 15, 2026. Here's what billing teams need to do.
This update from the Centers for Medicare & Medicaid Services directly affects how you document and bill IVIG therapy for conditions like pemphigus vulgaris and bullous pemphigoid. The policy does not list specific CPT or HCPCS codes in the data available — we note that below — but the clinical criteria and medical necessity requirements are what drive your denial risk here. If your practice or facility bills IVIG infusions for dermatologic autoimmune conditions, read this before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Dermatology, rheumatology, infusion therapy, hospital outpatient billing |
| Key Action | Audit your IVIG documentation against updated medical necessity criteria before May 15, 2026 |
CMS IVIG Coverage Criteria and Medical Necessity Requirements for Autoimmune Mucocutaneous Blistering Diseases 2026
The CMS IVIG coverage policy for autoimmune mucocutaneous blistering diseases ties reimbursement directly to documented medical necessity. That's not new. What billing teams need to understand is that modifications to this coverage policy — even when they look minor on the surface — almost always shift where the denial pressure lands. In this case, the pressure lands on documentation.
Autoimmune mucocutaneous blistering diseases are a category of serious, often life-threatening skin conditions. Pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita are the primary diagnoses in scope. These conditions involve autoantibody-mediated destruction of skin and mucous membranes, and standard treatments often fail to control them. IVIG becomes medically necessary when those standard treatments — typically systemic corticosteroids and immunosuppressants — don't produce adequate disease control.
CMS generally covers IVIG for these conditions when the patient has a confirmed diagnosis, has failed or cannot tolerate conventional therapy, and the treating physician documents the clinical rationale for IVIG use. That framework hasn't changed. What changes in a modification like this is how strictly those criteria are interpreted and what documentation you need to survive a post-payment audit or a prior authorization review.
Your medical necessity documentation needs to show three things clearly. First, the specific diagnosis — with lab confirmation where applicable, since pemphigus diagnoses typically require biopsy and direct immunofluorescence. Second, the treatment history — which agents were tried, at what doses, for how long, and why they failed. Third, the clinical decision to use IVIG — written by the treating physician, not reconstructed by a biller after the fact.
If your documentation doesn't walk a reviewer through that logic, you're exposed. The claim denial risk on IVIG for these conditions is high because the drug cost is significant and payers scrutinize high-cost infusion claims closely.
CMS IVIG Exclusions and Non-Covered Indications for Blistering Diseases
CMS does not cover IVIG for autoimmune mucocutaneous blistering diseases when the clinical criteria aren't met. That sounds obvious, but the specifics matter for billing.
IVIG is not covered as a first-line treatment. If a patient hasn't had an adequate trial of conventional therapy, CMS will not reimburse the infusion. "Adequate trial" means documented use at therapeutic doses for a clinically appropriate duration — not a brief exposure followed by patient preference for IVIG.
CMS also does not cover IVIG when the diagnosis is unconfirmed. A clinical suspicion isn't enough. You need pathology and immunofluorescence results in the chart before you submit. Billing without confirmed diagnosis documentation is a straight path to a claim denial and potential recoupment.
Conditions that mimic autoimmune blistering diseases — such as bullous drug eruptions or infection-related blistering — are not covered under this policy. The ICD-10 coding has to match the confirmed autoimmune etiology, not just the clinical presentation.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Pemphigus vulgaris — failed conventional therapy | Covered | Policy does not list specific codes | Requires biopsy confirmation and documented treatment failure |
| Bullous pemphigoid — refractory to standard treatment | Covered | Policy does not list specific codes | Medical necessity documentation required at each treatment course |
| Mucous membrane pemphigoid — inadequate response to first-line agents | Covered | Policy does not list specific codes | Prior authorization likely required; confirm with your MAC |
| Epidermolysis bullosa acquisita — conventional therapy failure | Covered | Policy does not list specific codes | High-cost drug — expect utilization management scrutiny |
| IVIG as first-line treatment (no prior therapy) | Not Covered | Policy does not list specific codes | Failure to document prior therapy is the top denial driver |
| Unconfirmed or clinically suspected diagnosis only | Not Covered | Policy does not list specific codes | Pathology and immunofluorescence required before billing |
| Non-autoimmune blistering conditions | Not Covered | Policy does not list specific codes | ICD-10 coding must reflect confirmed autoimmune etiology |
Note: This policy does not list specific CPT or HCPCS codes in the available data. See the Affected Codes section below.
CMS IVIG Billing Guidelines and Action Items 2026
This is where you take action before the effective date of May 15, 2026. The steps below are specific to IVIG billing for autoimmune mucocutaneous blistering diseases under this modified CMS coverage policy.
| # | Action Item |
|---|---|
| 1 | Pull your IVIG claims from the last 12 months and identify every claim tied to a blistering disease diagnosis. Look at the ICD-10 codes used. Make sure each one reflects a confirmed autoimmune etiology — not a symptom code or a non-specific skin condition code. If you find mismatches, assess your exposure and talk to your compliance officer before May 15, 2026. |
| 2 | Audit the medical records behind those claims. Check for three things: confirmed diagnosis with lab results, documented treatment history showing prior therapy failure, and a physician-authored clinical rationale for IVIG. If any of those three elements are missing from the chart, your documentation process needs to change now. |
| 3 | Confirm prior authorization requirements with your Medicare Administrative Contractor. CMS policy sets the coverage framework, but your MAC implements it regionally. Prior authorization requirements for high-cost infusions like IVIG vary. Call your MAC's provider line or check their website for current prior auth requirements before you bill under the updated policy. |
| 4 | Update your IVIG infusion billing guidelines internally. If your revenue cycle team has a charge capture workflow for IVIG, revise it to include a documentation checklist tied to this policy's criteria. Every IVIG claim for a blistering disease indication should require a checklist sign-off before it goes out the door. |
| 5 | Train your clinical documentation team on the specificity CMS expects. Dermatologists and rheumatologists sometimes document in ways that make clinical sense but don't translate cleanly to billing criteria. "Patient not responding to steroids" is weaker than "Patient completed a 16-week course of prednisone at 1 mg/kg/day with inadequate disease control per PDAI scoring." The second version survives an audit. The first one doesn't. |
| 6 | Set a calendar reminder to recheck this policy at the effective date. Policy modifications sometimes come with additional sub-regulatory guidance — local coverage determinations, billing articles, or contractor-specific instructions — that publish after the main policy update. Check your MAC's website around May 15, 2026 for any companion documents. |
If your IVIG volume for dermatologic autoimmune conditions is high, loop in your compliance officer now. The financial exposure on a post-payment audit for IVIG claims is significant, and this modification is a signal that CMS is paying attention to this category.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for IVIG Therapy Under This CMS Policy
A Note on Code Availability
This policy does not list specific CPT or HCPCS codes in the data available at time of publication. We do not fabricate codes. Listing invented codes here would be worse than useful — it would create billing errors.
What we can tell you is this: IVIG infusions are typically billed using HCPCS J-codes for the drug and CPT codes for the infusion administration. The specific codes depend on the IVIG product administered, the dose, and the site of service. Your MAC's local coverage determination for IVIG, if one exists, will list the applicable codes. Check the source policy at PayerPolicy for any code-level updates as they become available.
What to Look For When You Pull Codes
When you verify codes with your MAC or through your billing system, you're looking for:
- The HCPCS J-code for the specific IVIG product (different products have different J-codes)
- The CPT infusion administration code for the site of service (outpatient hospital, physician office, or infusion center)
- The ICD-10-CM diagnosis codes that confirm autoimmune mucocutaneous blistering disease — not symptom or unspecified codes
The ICD-10 coding is where many IVIG claims for these conditions fail. Pemphigus vulgaris, bullous pemphigoid, and related conditions have specific ICD-10 codes. Using a non-specific skin disorder code when a specific autoimmune code exists is a documentation and coding error that survives the claim submission process and then gets caught on audit. Fix the coding before May 15, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.